Reuters logo
6 months ago
BRIEF-Bird Rock Bio receives approval to start first in human clinical trial for Namacizumab, enters into agreement with GE Healthcare for process development and scale-up to provide clinical phase 2 cGMP material
January 11, 2017 / 1:39 PM / 6 months ago

BRIEF-Bird Rock Bio receives approval to start first in human clinical trial for Namacizumab, enters into agreement with GE Healthcare for process development and scale-up to provide clinical phase 2 cGMP material

1 Min Read

Jan 11 (Reuters) - General Electric Co

* Bird Rock Bio receives approval to start first in human clinical trial for Namacizumab, enters into agreement with GE Healthcare for process development and scale-up to provide clinical phase 2 cGMP material, and enters into a collaboration and option agreement with Janssen Pharmaceuticals Inc

* Bird Rock Bio says has received approval for initiation of a two-part phase 1 clinical trial for Namacizumab

* Bird Rock Bio says entered into agreement with GE Healthcare for process development, formulation, manufacture of Namacizumab in preparation for phase 2 studies

* Bird Rock Bio says phase 1 trial, process development, phase 2 preparation to be funded under collaboration, option agreement with Janssen Pharmaceuticals

* Bird Rock Bio says entered collaboration, option agreement, under which Janssen Pharmaceuticals has exclusive right to acquire co after phase 1 data readout Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below